{"schema_version":"secwatch.filing_event.v1","accession":"0001326190-23-000040","form_type":"8-K","ticker":"ALT","cik":"0001326190","company_name":"Altimmune, Inc.","filed_at":"2023-09-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.582322+00:00","generated_at":"2026-06-10T07:28:51.085856+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Altimmune 2023 annual meeting results: all director nominees elected, say-on-pay approved","bullets":["All 9 director nominees elected; highest vote for was 21.9M, lowest 19.4M.","Say-on-pay advisory vote passed: 16.8M for, 5.2M against, 12.4M broker non-votes.","Stockholders selected 1-year frequency for future say-on-pay votes (21.6M for 1-year).","Ernst & Young ratified as auditor for FY2023 with 34.3M for, 153K against.","Adjournment proposal authorized with 27.7M for vs 6.7M against."],"urls":{"canonical":"https://secwatch.observer/filing/0001326190-23-000040","json":"https://secwatch.observer/filing/0001326190-23-000040.json","markdown":"https://secwatch.observer/filing/0001326190-23-000040.md","text":"https://secwatch.observer/filing/0001326190-23-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326190/000132619023000040/0001326190-23-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326190/000132619023000040/alt-20230928x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T07:28:51.085856+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0003f056731821d2f6ffb3181a4ad7bd6169ab2b","claim":"Altimmune, Inc. shareholders approved Vote to authorize the adjournment of the 2023 Annual Meeting to enable the Board of Directors to solicit additional proxies at the 2023-09-28 meeting.","evidence_excerpt":"Proposal No. 5 : Vote to authorize the adjournment of the 2023 Annual Meeting to enable the Board of Directors to solicit additional proxies. The results were as follows: ​ ​ ​ ​ ​ For ​ Against ​ Abstain 27,712,554 ​ 6,744,992 104,432","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326190/000132619023000040/0001326190-23-000040-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-09-28"}],"fact_type":"shareholder_vote"},{"claim_id":"39456354286ed8fe777d0e91b7390ba68dc8c86d","claim":"Altimmune, Inc. shareholders approved Election of Directors at the 2023-09-28 meeting.","evidence_excerpt":"Proposal No. 1 : Election of Directors. The results were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Broker Director ​ For ​ Withhold ​ Non-Votes Mitchel Sayare, Ph.D., Chairman ​ 21,844,990 316,470 12,400,518 Vipin K. Garg, Ph.D. ​ 21,885,151 276,309 12,400,518 David J. Drutz, M.D. ​ 19,880,376 2,281,084 12,400,518 John M. Gill ​ 21,588,792 572,668 12,400,518 Philip L. Hodges ​ 21,810,125 351,335 12,400,518 Diane Jorkasky, M.D. ​ 21,824,133 337,327 12,400,518 Wayne Pisano ​ 19,385,875 2,775,585 12,400,518 Klaus O. Schafer, M.D., MPH 21,823,016 338,444 12,400,518 Catherine Sohn, Pharm D 21,912,287 249,173 12,400,518","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326190/000132619023000040/0001326190-23-000040-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-09-28"}],"fact_type":"shareholder_vote"},{"claim_id":"d61af265abda3eb3336424d6b865c34a893ebaa1","claim":"Altimmune, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023 at the 2023-09-28 meeting.","evidence_excerpt":"Proposal No. 2 : Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023. The results were as follows: ​ ​ ​ ​ ​ For ​ Against ​ Abstain 34,318,768 ​ 153,149 90,061","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326190/000132619023000040/0001326190-23-000040-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-09-28"}],"fact_type":"shareholder_vote"},{"claim_id":"d99c5d596489c7fe4529bd2671c5d09a5c55a494","claim":"Altimmune, Inc. shareholders approved Advisory vote on the Compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the SEC's compensation rules at the 2023-09-28 meeting.","evidence_excerpt":"Proposal No. 3 : Advisory vote on the Compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the SEC's compensation rules (referred to as the \"say-on-pay\" proposal). The results were as follows: ​ ​ ​ ​ ​ ​ ​ For ​ Against ​ Abstain ​ Broker Non-Votes 16,834,432 ​ 5,221,648 ​ 105,380 12,400,518","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326190/000132619023000040/0001326190-23-000040-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-09-28"}],"fact_type":"shareholder_vote"},{"claim_id":"e3a1ab9ac6593710ac01a61e8e836f1aca05000f","claim":"Altimmune, Inc. shareholders approved Advisory vote on the frequency with which the Company will hold a non-binding, advisory vote on the compensation of its named executive officers as disclosed in the Proxy Statement pursuant to the SEC's compensation rules at the 2023-09-28 meeting.","evidence_excerpt":"Proposal No. 4 : Advisory vote on the frequency with which the Company will hold a non-binding, advisory vote on the compensation of its named executive officers as disclosed in the Proxy Statement pursuant to the SEC's compensation rules (referred to as the \"frequency of say-on-pay\" proposal). The results were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ 1 Year ​ 2 Years ​ 3 Years ​ Abstain ​ Broker Non-Votes 21,595,590 ​ 80,595 352,096 133,179 12,400,518","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326190/000132619023000040/0001326190-23-000040-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-09-28"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}